Volume 73, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Medical records of 77 patients with Q fever pneumonia that was serologically confirmed by enzyme-linked immunosorbent assay were studied to compare the clinical efficacy of doxycycline, clarithromycin, and moxifloxacin. The mean times to defervescence were 2.4 days for those receiving doxycycline, 1.9 days for those receiving clarithromycin, and 2.2 days for those receiving moxifloxacin. There were no interruptions of the regimens in any groups because of side effects, and outcome was favorable in all patients with no complications or relapses during follow-up. This efficacy of clarithromycin and moxifloxacin, together with their safety profiles, suggest that these alternative agents in the treatment of Q fever pneumonia could also be used as the first-line therapy.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Spelman DW, 1982. Q fever: a study of 111 consecutive cases. Med J Aust 1 : 547–553. [Google Scholar]
  2. Dumler JS, 2002. Q fever. Curr Treat Options Infect Dis 4 : 437–445. [Google Scholar]
  3. Marrie TJ, 2004. Q fever pneumonia. Curr Opin Infect Dis 17 : 137–142. [Google Scholar]
  4. File TM Jr, Tan JS, 2003. International guidelines for the treatment of community-acquired pneumonia in adult: the role of macrolides. Drugs 63 : 181–205. [Google Scholar]
  5. Hoeffken D, Talan D, Larsen LS, Peloquin S, Choudri SH, Haverstock D, Jackson P, Church D, 2004. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens. Eur J Clin Microbiol Infect Dis 23 : 772–775. [Google Scholar]
  6. Maurin M, Benoliel AM, Bongrand P, Raoult D, 1992. Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm. J Infect Dis 166 : 1097–1102. [Google Scholar]
  7. Maurin M, Raoult D, 1993. In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetii to clarithromycin. Antimicrob Agents Chemother 37 : 2633–2637. [Google Scholar]
  8. Gikas A, Spyridaki I, Psaroulaki A, Kofteridis DP, Tselentis Y, 1998. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. Antimicrob Agents Chemother 42 : 2747–2748. [Google Scholar]
  9. Rolain J-M, Maurin M, Raoult D, 2001. Bacteriostatic and bactericidal activities of moxifloxacin against Coxiella burnetii. Antimicrob Agents Chemother 45 : 301–302. [Google Scholar]
  10. Lever MS, Bewley KR, Dowsett B, Lloyd G, 2004. In vitro susceptibility of Coxiella burnetii to azithromycin, doxycycline, ciprofloxacin and a range of newer fluoroquinolones. Int J Antimicrob Agents 24 : 194–196. [Google Scholar]
  11. Gikas A, Kofteridis DP, Manios A, Pediaditis J, Tselentis Y, 2001. Newer macrolides as empiric treatment for acute Q fever infection. Antimicrob Agents Chemother 45 : 3644–3646. [Google Scholar]
  12. Dzelalija B, Morovic M, Stankovic S, Vukic L, Dobec M, Dujella J, 1990. Clinical spectrum of rickettsioses in the Zadar area. Lijec Vjesn 112 : 102–105. [Google Scholar]
  13. Gikas A, Spyridaki I, Scoulica E, Psaroulaki A, Tselentis Y, 2001. In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin. Antimicrob Agents Chemother 45 : 3276–3278. [Google Scholar]
  14. Maurin M, Raoult D, 1999. Q fever. Clin Microbiol Rev 12 : 518–553. [Google Scholar]

Data & Media loading...

  • Received : 11 Feb 2005
  • Accepted : 15 Apr 2005

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error